Review Finds Artificial Intelligence Mammography Tools Face Significant Clinical Limitations

Investigators led by the UCLA Health Jonsson Comprehensive Cancer Center published a review examining commercially available artificial intelligence tools used to assist in interpreting screening mammograms. Los Angeles Business Journal reported that artificial intelligence systems may help radiologists detect subtle signs of breast cancer that are missed in routine screenings. The systems may also identify patterns linked to higher cancer risk before lesions become visible on mammograms. [1]

Despite the potential benefits, researchers noted that significant limitations remain regarding these technologies. According to Los Angeles Business Journal, the publication in the Journal of Breast Imaging summarized existing research on commercial software, concluding that the overall clinical benefit of these tools is still uncertain. [1]

The research highlights broader industry developments in predictive software for mammography. Biostatistician Shu Jiang co-founded Prognosia Incorporated, a company that develops artificial intelligence models to predict breast cancer risk from digital mammograms. Its tool, Prognosia Breast, received Breakthrough Device Designation from the United States Food and Drug Administration in June 2025 before Lunit acquired the company in September 2025. [2]